Novo Nordisk has licensed Genmab’s DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programmes.

The bispecific antibodies being developed will target a disease area outside of cancer therapeutics.

Genmab’s DuoBody platform is a proprietary technology platform for the discovery and development of bispecific antibodies, which binds to two different epitopes either on the same or on different targets.

“Our proprietary DuoBody technology can be used to create bispecific antibodies that target a wide variety of disease areas.”

DuoBody platform generated bispecific antibodies are expected to improve antibody therapy of cancer, autoimmune, and infectious and central nervous system disease.

Genmab CEO Jan van de Winkel said: “Our proprietary DuoBody technology can be used to create bispecific antibodies that target a wide variety of disease areas.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Today’s agreement with Novo Nordisk is an example of how we can leverage access to our unique state-of-the art antibody expertise and collaborations to generate diverse revenue streams in areas beyond cancer.”

As part of the deal, Novo Nordisk will pay an upfront payment of $2m to Genmab.

Novo Nordisk is also eligible to maintain exclusivity or take the licences forward on a non-exclusive basis, after an initial period of exclusivity for the two target combinations.

The deal will allow Genmab to receive potential development, regulatory and sales milestones of up to $250m for each exclusive licence of around $200m for each non-exclusive licence.

The company will also receive single-digit royalties on sales of any commercialised products.